The DOI matches its Crossref record; 110 of the 114 references it cites were found in a registry or an index.
The Dual Roles of NRF2 in Cancer
Open accessAbstract
NRF2 has been traditionally considered as a tumor suppressor because its cytoprotective functions are deemed to be the main cellular defense mechanism against exogenous and endogenous insults, including xenobiotics and oxidative stress. However, several recent studies demonstrate that hyperactivation of the NRF2 pathway creates an environment that favors the survival of normal as well as malignant cells, protecting them against oxidative stress, chemotherapeutic agents, and radiotherapy. In a rapidly advancing field, this review summarizes some of the known mechanisms by which NRF2 can exert its oncogenic functions, and describes the current status of NRF2 inhibitors, providing a clear rationale for the consideration of NRF2 as a powerful putative therapeutic target in cancer treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [8]
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [8]
In the citing paper
“In this regard, mutations to NRF2 and its regulator KEAP1 have been found in cancer cells, supporting the supposition that antioxidant genes are pivotal in tumor progression59–62.”
From ROS in cancer therapy: the bright side of the moon (2020) · cites this paper as [61]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., Sou, Y.-S., Ueno, I., Sakamoto, A., Tong, K. I., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2021 · Cited by 2,288
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Nrf2–Keap1 defines a physiologically important stress response mechanism
Motohashi, H., & Yamamoto, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.003 · Cited by 1,725 · cited 1×
“NRF2: Tumor Suppressor or Oncogene? The main function of the transcription factor NRF2 [also known as NFE2L2, nuclear factor (erythroid-derived-2)-like 2] is to activate the cellular antioxidant response by inducing the transcription of several genes to protect cells from the effects of exogenous and endogenous insult…”
BackgroundMoi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9926 · Cited by 1,607
Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Benmaad, I., Caldéraro, J., Bioulac‐Sage, P., Letexier, M., Degos, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2256 · Cited by 1,522
Cited by
Sorted by citations
Items 301–400 of 637
Noh, Y., Jeon, S., & Shin, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.31870 · Cited by 28
SLC7A11 in hepatocellular carcinoma: potential mechanisms, regulation, and clinical significance
Li, T.-Z. (2024) · American Journal of Cancer Research · doi:10.62347/kgcl7357 · Cited by 25
He, J., Zhang, Y., Luo, S., Zhao, Z., Mo, T., Guan, H., Li, H., Bian, Z., Zhang, X., Qiu, S., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101250 · Cited by 33
Therapeutic Interventions to Block Oxidative Stress-Associated Pathologies
Prasad, N., Ramteke, P., Dholia, N., & Yadav, U. C. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805417-8.00027-5 · Cited by 25
NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma
Yen, C., & Hsiao, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113503 · Cited by 25
Mondal, D., Narwani, D., Notta, S., Ghaffar, D., Mardhekar, N. M., & Quadri, S. S. A. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.71 · Cited by 25
Xia, R. M., Tang, H., Shen, J., Xu, S., Liang, Y., Zhang, Y., Gong, X., Min, Y., Zhang, D., Tao, C., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01857-4 · Cited by 25
Role of Nrf2 in bisphenol effects: a review study
Salehabadi, A., Farkhondeh, T., Harifi-Mood, M. S., Aschner, M., & Samarghandian, S. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-20996-3 · Cited by 25
Oxidative Stress in Urolithiasis
Boonla, C. (2018) · InTech eBooks · doi:10.5772/intechopen.75366 · Cited by 24
Cai, M., Chen, M., Ma, P., Wu, J., Lu, H., Zhang, S., Liu, J., Zhao, X., Zhuang, G., Yu, Z., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31975 · Cited by 25
Limitations to adaptive homeostasis in an hyperoxia-induced model of accelerated ageing
Pomatto, L. C. D., Sun, P. Y., Yu, K., Gullapalli, S., Bwiza, C. P., Sisliyan, C., Wong, S., Zhang, H., Forman, H. J., Oliver, P. L., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101194 · Cited by 25
Lin, W. Y., Wang, X., Diao, M., Wang, Y., Zhao, R., Chen, J., Liao, Y., Long, Q., & Meng, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03418-x · Cited by 26
Nrf2/Keap1/ARE regulation by plant secondary metabolites: a new horizon in brain tumor management
Dewanjee, S., Bhattacharya, H., Bhattacharyya, C., Chakraborty, P., Fleishman, J. S., Alexiou, A. T., Papadakis, M., & Jha, S. K. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01878-2 · Cited by 29
Abrus agglutinin inhibits oral carcinogenesis through inactivation of NRF2 signaling pathway.
Panigrahi, D. P., Bhol, C. S., Niveta, R., Nagini, S., Patil, S., Maiti, T. K., & Bhutia, S. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.11.079 · Cited by 24
Lastra, D., Escoll, M., & Cuadrado, A. (2022) · Antioxidants · doi:10.3390/antiox11050946 · Cited by 24
Li, Y., Qian, W., Wang, D., Meng, Y., Wang, X., Chen, Y., Li, X., Xie, C., Zhong, C., & Fu, S. (2018) · Journal of Applied Toxicology · doi:10.1002/jat.3636 · Cited by 24
Limited expression of Nrf2 in neurons across the central nervous system
Levings, D. C., Pathak, S. S., Yang, Y., & Slattery, M. G. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102830 · Cited by 23
Diosmetin: A dietary flavone as modulator of signaling pathways in cancer progression
Raza, W., Meena, A., & Luqman, S. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23774 · Cited by 26
Han, L., Zhou, Z., Ma, Y., Batistel, F., Osorio, J. S., & Loor, J. J. (2018) · Journal of Dairy Science · doi:10.3168/jds.2017-14257 · Cited by 23
Zhao, F., Hong, X., Li, D., Wei, Z., Ci, X., & Zhang, S. (2021) · Medical Oncology · doi:10.1007/s12032-021-01501-1 · Cited by 23
Karagiannis, D., Wu, W., Li, A. M., Hayashi, M., Chen, X., Yip, M., Mangipudy, V. S., Xu, X., Rivera, F. J. S., Soto‐Feliciano, Y. M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113629 · Cited by 26
The role of nuclear factor erythroid 2-related factor 2 (NRF2) in arsenic toxicity
El-Mahrouk, S. R., El‐Ghiaty, M. A., & El‐Kadi, A. O. S. (2024) · Journal of Environmental Sciences · doi:10.1016/j.jes.2024.02.027 · Cited by 26
Aydın, Y., Stephens, C. M., Chava, S. P., Heidari, Z., Panigrahi, R., Williams, D. D., Wiltz, K., Bell, A., Wilson, W., Krzysztof Reiss, F., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.06.022 · Cited by 23
Corilagin induces apoptosis and autophagy in NRF2‑addicted U251 glioma cell line
Liu, J., Qin, X., Ma, W., Jia, S., Zhang, X., Yang, X., Pan, D., & Jin, F. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11959 · Cited by 22
Danilovic, D. L. S., de Mello, E. S., Frazzatto, E., Wakamatsu, A., Jorge, A. A. L., Hoff, A. O., & Marui, S. (2018) · Head & Neck · doi:10.1002/hed.25105 · Cited by 22
Rostila, A., Anttila, S. L., Lalowski, M. M., Vuopala, K. S., Toljamo, T., Lindström, I., Baumann, M., & Puustinen, A. (2019) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000537 · Cited by 22
Song, C., Kim, N., Nam, R. H., Choi, S. I., Son, J. H., Yu, J. E., Shin, E. H., Lee, H., Kim, D.-H., & Surh, Y. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114279 · Cited by 23
Yu, J., Yang, Y., Li, S., & Meng, P. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10378 · Cited by 22
RetractedSamec, M., Mazuráková, A., Lučanský, V., Koklesová, L., Péčová, R., Péč, M. J., Golubnitschaja, O., AL-Ishaq, R. K., Čaprnda, M., Gašpar, Ľ., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175655 · Cited by 22
Role of Mangiferin in Management of Cancers through Modulation of Signal Transduction Pathways
Rahmani, A. H., Almatroudi, A., Allemailem, K. S., Alharbi, H. O. A., Alwanian, W. M., Alhunayhani, B. A., Algahtani, M., Theyab, A., Almansour, N. M., Algefary, A. N., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11123205 · Cited by 22
Modulating Nrf2 to control lipid peroxidation and ferroptosis: implications for cancer management
Tunc, R., Ateş, İ., Yılmaz, B., Medoro, A., Davinelli, S., Süzen, S., & Saso, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1701249 · Cited by 21
The Effects of Dietary Supplements that Overactivate the Nrf2/ARE System
Smith, R. E. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190517113533 · Cited by 22
Chen, Y., Chang, H., Hsiao, H., Chen, Y., Kuo, Y.-P., Yen, F., & Yen, C. (2021) · Antioxidants · doi:10.3390/antiox10040544 · Cited by 21
Reactive oxygen species: Key players in the anticancer effects of apigenin?
Oyenihi, O. R., Oyenihi, A. B., Alabi, T. D., Tade, O. G., Adeyanju, A. A., & Oguntibeju, O. O. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14060 · Cited by 21
Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis (Review)
Kobayashi, H., Imanaka, S., & Shigetomi, H. (2022) · Oncology Letters · doi:10.3892/ol.2022.13200 · Cited by 21
Li, C., Chang, C., Tsang, Y.-L., Fang, S.-H., Chen, S., & Chiang, A. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109273 · Cited by 21
New perspectives on ferroptosis and its role in hepatocellular carcinoma
Cong, T., Luo, Y., Fu, Y. H. H., Liu, Y., Li, Y., & Li, X. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002327 · Cited by 21
A New Nrf2 Inhibitor Enhances Chemotherapeutic Effects in Glioblastoma Cells Carrying p53 Mutations
Afjei, R., Sadeghipour, N., Sukumar, U. K., Pandrala, M., Kumar, V., Malhotra, S. V., Massoud, T. F., & Paulmurugan, R. (2022) · Cancers · doi:10.3390/cancers14246120 · Cited by 21
Dietary modulation of gut microbiota affects susceptibility to drug-induced liver injury
Pan, H., Song, D., Wang, Z., Yang, X., Luo, P., Li, W., Li, Y., Gong, M., & Zhang, C. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2439534 · Cited by 22
Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology
Czogalla, B., Kahaly, M., Mayr, D. C., Schmoeckel, E., Niesler, B., Hester, A., Zeder-Göß, C., Kolben, T., Burges, A., Mahner, S., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s210004 · Cited by 21
Nrf2 in Neoplastic and Non-Neoplastic Liver Diseases
Orrù, C., Giordano, S., & Columbano, A. (2020) · Cancers · doi:10.3390/cancers12102932 · Cited by 21
Self-citationDietary Phytochemicals Targeting Nrf2 to Enhance the Radiosensitivity of Cancer
Wang, P., Long, F., Lin, H., Wang, S., & Wang, T. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/7848811 · Cited by 22
Elkhalifa, D. H., Al-Ziftawi, N. H., Awaisu, A., Alali, F. Q., & Khalil, A. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1251895 · Cited by 22
Yang, L., Tang, H., Wang, J., Xu, D., Xuan, R., Xie, S., Xu, P., & Li, X. (2025) · BMC Biology · doi:10.1186/s12915-025-02126-w · Cited by 20
Chen, C.-H., Hsieh, Y., Yang, P., Liu, Y., & Cho, E.-C. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.147 · Cited by 20
p62 functions as a signal hub in metal carcinogenesis
Zhang, Z., & Costa, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.014 · Cited by 21
Xiao, Q., Liu, Y., Jiang, G., Liu, Y., Huang, Y., Liu, W., & Zhang, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114302 · Cited by 20
Zhou, J., Fang, F., Qi, J., Li, T., Zhang, L., Liu, H., Lv, J., Xu, T., Wu, F., Song, C., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.10.274 · Cited by 20
Jiang, Y., Ni, S., Xiao, B., & Jia, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.019 · Cited by 22
Allicin Overcomes Doxorubicin Resistance of Breast Cancer Cells by Targeting the Nrf2 Pathway
Shi, G., Li, X., Wang, W., Hou, L., Yin, L., & Wang, L. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01215-x · Cited by 21
Kim, H. G., Kim, C. W., Lee, D. H., Lee, J., Oh, E., & Park, H. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184366 · Cited by 20
Taheri, Z., Aghdaei, H. A., Irani, S., Modarressi, M. H., & Noormohammadi, Z. (2020) · Reports of Biochemistry and Molecular Biology · doi:10.29252/rbmb.9.1.33 · Cited by 20
Karampa, A. D., GOUSSIA, A. C., Glantzounis, G. K., Mastoridou, E. M., Anastasopoulos, N.-A., & Charchanti, A. V. (2022) · Cancers · doi:10.3390/cancers14030760 · Cited by 20
KEAP1-NRF2 Interaction in Cancer: Competitive Interactors and Their Role in Carcinogenesis
Oskomić, M., Tomić, A., Barbarić, L., Matić, A., Kindl, D. C., & Matovina, M. (2025) · Cancers · doi:10.3390/cancers17030447 · Cited by 22
Gankyrin as a potential therapeutic target for cancer
Wang, C., & Cheng, L. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0474-8 · Cited by 19
Grigolon, G., Araldi, E., Erni, R., Wu, J. Y., Thomas, C., Fortezza, M. L., Laube, B., Pöhlmann, D., Stoffel, M., Zarse, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27732-4 · Cited by 21
HRD1 in human malignant neoplasms: Molecular mechanisms and novel therapeutic strategy for cancer
Karamali, N., Ebrahimnezhad, S., Moghadam, R. K., Daneshfar, N., & Rezaiemanesh, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120620 · Cited by 20
Lin, H., Lim, S.-W., Hsu, T., Yang, W., Huang, C., Tsai, Y.-T., Chang, W., & Ko, C. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/4081380 · Cited by 19
Knockdown of Nrf2 radiosensitizes glioma cells by inducing redox stress and apoptosis in hypoxia
Tang, T. F., Jia, Y., Liang, H., Han, Y., Cong, Z., Wang, H., & Ji, X. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-1420 · Cited by 19
Zhang, H., Xu, X., Yan, D., Ren, C., Zhang, J., Gu, M., Wang, Y., Wu, P., Li, Z., Kong, L., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c20312 · Cited by 20
Benedetti, S., Nasoni, M. G., Luchetti, F., & Palma, F. (2023) · Toxicology in Vitro · doi:10.1016/j.tiv.2023.105705 · Cited by 19
Peiminine triggers ferroptosis to inhibit breast cancer growth through triggering Nrf2 signaling
Yi, N., Wang, L., Jiang, Z., Xu, G., Li, L., Zhang, Y., & Tan, Y. (2024) · Tissue and Cell · doi:10.1016/j.tice.2024.102323 · Cited by 19
Transcription Factor NRF2 in Shaping Myeloid Cell Differentiation and Function
Pfefferlé, M., & Vallelian, F. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-62731-6_8 · Cited by 18
Activating or Inhibiting Nrf2?
Chu, X., Liu, Y.-M., & Zhang, H. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.002 · Cited by 19
Rossetti, A., Petragnano, F., Milazzo, L., Vulcano, F., Macioce, G., Codenotti, S., Cassandri, M., Pomella, S., Cicchetti, F., Fasciani, I., et al. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1928786 · Cited by 19
Cooperation Between the NRF2 Pathway and Oncogenic β‐catenin During HCC Tumorigenesis
Savall, M., Senni, N., Lagoutte, I., Sohier, P., Dentin, R., Romagnolo, B., Perret, C., & Bossard, P. (2021) · Hepatology Communications · doi:10.1002/hep4.1746 · Cited by 20
O'Cathail, S. M., Wu, C., Thomas, R. J., Hawkins, M., Maughan, T., & Lewis, A. (2021) · Antioxidants · doi:10.3390/antiox10091380 · Cited by 19
The Antioxidant Ergothioneine Alleviates Cisplatin-Induced Hearing Loss Through the Nrf2 Pathway
Zhao, W., Wu, F., Hu, R., Lou, J., Chen, G., Cai, Z., & Chen, S. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0648 · Cited by 18
Limonin induces apoptosis of HL‐60 cells by inhibiting NQO1 activity
Chen, Y., Liang, J., Liang, X. H., Chen, J., Wang, Y., Cao, J., Sun, C., Ye, J., & Chen, Q. (2021) · Food Science & Nutrition · doi:10.1002/fsn3.2109 · Cited by 18
Exploring the multifaceted role of NRF2 in brain physiology and cancer: A comprehensive review
Moubarak, M. M., Zottola, A. C. P., Larrieu, C. M., Cuvellier, S., Daubon, T., & Martin, O. C. B. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad160 · Cited by 22
Augello, F. R., Lombardi, F., Ciummo, V., Ciafarone, A., Cifone, M. G., Cinque, B., & Palumbo, P. (2025) · Antioxidants · doi:10.3390/antiox14040459 · Cited by 18
Zhang, B., Ma, Z., Tan, B., & Lin, N. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1559824 · Cited by 18
Orrù, C., Perra, A., Kowalik, M. A., Rizzolio, S., Puliga, E., Cabras, L., Giordano, S., & Columbano, A. (2020) · Cancers · doi:10.3390/cancers12082305 · Cited by 18
Self-citationNRF2 metagene signature is a novel prognostic biomarker in colorectal cancer
O'Cathail, S. M., Wu, C., Lewis, A., Holmes, C. C., Hawkins, M., & Maughan, T. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.08.006 · Cited by 18
Li, Y., Lu, Z., Zhan, F., Yang, M., Zhao, L., Shi, F., Li, J., Lin, L., & Qin, Z. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.736474 · Cited by 18
Wang, M., Ren, Y., Hu, S., Liu, K., Qiu, L., & Zhang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.707032 · Cited by 18
Mutant p53–Nrf2 axis regulates the proteasome machinery in cancer
Lisek, K., Walerych, D., & Sal, G. D. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2016.1217967 · Cited by 18
Weight loss enhances hepatic antioxidant status in a NAFLD model induced by high-fat diet
Mendes, I. K. S., Matsuura, C., Águila, M. B., Daleprane, J. B., Martins, M. A., Mury, W. V., & Brunini, T. M. C. (2017) · Applied Physiology Nutrition and Metabolism · doi:10.1139/apnm-2017-0317 · Cited by 18
Gao, Y., Zhao, Z., Meng, X., Chen, H., & Fu, G. (2018) · Oncology Letters · doi:10.3892/ol.2018.8799 · Cited by 18
Liu, M., Wang, D., Luo, Y., Hu, L., Bi, Y., Ji, J., Huang, H., Wang, G., Zhu, L., Ma, J., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03473-6 · Cited by 17
Kang, C., Song, C., Kim, N., Nam, R. H., Choi, S. I., Yu, J. E., Nho, H., Choi, J. A., Kim, J. W., Na, H. Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679324 · Cited by 17
Khan, M. G. M., Boufaied, N., Yeganeh, M., Kandhi, R., Petkiewicz, S., Sharma, A., Yoshimura, A., Ferbeyre, G., Labbé, D. P., Ramanathan, S., et al. (2023) · Cancers · doi:10.3390/cancers15030905 · Cited by 17
Research progress on antitumor mechanisms and molecular targets of Inula sesquiterpene lactones
Cao, F., Chu, C., Qin, J., & Guan, X. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00870-1 · Cited by 17
SOCS1 expression in cancer cells: potential roles in promoting antitumor immunity
Ilangumaran, S., Gui, Y., Shukla, A., & Ramanathan, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362224 · Cited by 18
Wang, L., Qu, G., Gao, Y., Su, L., Ye, Q., Jiang, F., Zhao, B., & Miao, J. (2018) · RSC Advances · doi:10.1039/c7ra11935f · Cited by 17
Role of human Keap1 S53 and S293 residues in modulating the binding of Keap1 to Nrf2
Wei, S., Pei, Y., Wang, Y., Guan, H., Huang, Y., Xing, T. Y., Johnson, R. W., & Wang, D. (2018) · Biochimie · doi:10.1016/j.biochi.2018.12.008 · Cited by 17
Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors
Sparaneo, A., Fabrizio, F. P., la Torre, A., Graziano, P., Maïo, M. D., Fontana, A., Bisceglia, M., Rossi, A., Pizzolitto, S., Maglio, G. D., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102531 · Cited by 17
Xu, Y., Yang, Y., Huang, Y., Ma, Q., Shang, J., Guo, J., Cao, X., Wang, X., & Li, M. (2020) · Journal of Cancer · doi:10.7150/jca.50605 · Cited by 17
Gwon, Y., Oh, J., & Kim, J. (2020) · Applied Biological Chemistry · doi:10.1186/s13765-020-00578-y · Cited by 17
Aralbaeva, A. N., Mamataeva, А. Т., Zhaparkulova, N., Utegalieva, R. S., Khanin, M., Danilenko, M., & Murzakhmetova, M. K. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.085 · Cited by 17
Chang, L., Fan, C., Tseng, W., & Hua, C. (2019) · Cancer Biomarkers · doi:10.3233/cbm-190828 · Cited by 17
Alves, A. D. F., de Moura, A. C., Andreolla, H. F., da Veiga, A. B. G., Fiegenbaum, M., Giovenardi, M., & Almeida, S. (2021) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2019-0373 · Cited by 16
NRF2 as a ferroptosis gatekeeper in colorectal cancer: implications for therapy
El‐Sehrawy, A. A. M. A., Al-dulaimi, A. A., Alkhathami, A. G., RenukaJyothi, S., Panigrahi, R., Pargaien, A. V., Singh, U., Husseini, A., & Alnajar, M. J. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04324-3 · Cited by 16
NRF2-Driven KEAP1 Transcription in Human Lung Cancer
Tian, Y., Liu, Q., Yu, S., Chu, Q., Chen, Y., Wu, K., & Wang, L. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0108 · Cited by 15
Li, Y., Chen, Z., Xiao, Y., Gao, F., Zhan, F., Lu, Z., Huang, Z., Wei, X., Su, F., Shi, F., et al. (2023) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2023.108686 · Cited by 15
Mitophagy in tumor: foe or friend?
Li, L., & Hu, F. (2023) · Endokrynologia Polska · doi:10.5603/ep.95652 · Cited by 15
Isoliquiritigenin as a modulator of the Nrf2 signaling pathway: potential therapeutic implications
Qiu, M., Ma, K., Zhang, J., Zhao, Z., Wang, S., Wang, Q., & Xu, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1395735 · Cited by 18
Harada, M., Yoneda, A., Haruyama, S., Yabuki, K., Honma, Y., Hiura, M., Shibata, M., Matsuoka, H., & Uchiwa, Y. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8703-16 · Cited by 15
Banella, C., Catalano, G., Travaglini, S., Divona, M., Masciarelli, S., Guerrera, G., Fazi, F., Lo‐Coco, F., Voso, M. T., & Noguera, N. I. (2019) · Cancers · doi:10.3390/cancers12010095 · Cited by 15
Morsy, H. M., Ahmed, O. M., Zoheir, K. M. A., & Abdel‐Moneim, A. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01852-2 · Cited by 15
Metadata
- Authors
- Menegon, S., Columbano, A., & Giordano, S.
- Affiliations
- Candiolo Cancer Institute (IT)
- University of Cagliari (IT)
- Corresponding author
- Menegon, Silvia
- Columbano, Amedeo
- Giordano, Silvia
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 22
- Issue
- 7
- Pages
- 578-593
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2417535489
- Cited by
- 633
- References
- 114
- Citations by year
- 2026: 28 · 2025: 43 · 2024: 64 · 2023: 60 · 2022: 74 · 2021: 75 · 2020: 69 · 2019: 72 · 2018: 73 · 2017: 57 · 2016: 16
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Trends in Molecular Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by-nc-nd)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (15464, 15279, IG-15279)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- Nrf2, Nrf2 signaling, oncogenic function, tumor suppressor, oxidative stress, chemoresistance, radioresistance (biology), Nrf2 inhibitors, therapeutic target, cancer
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Oxidative Stress, MicroRNAs, Epigenesis, Genetic, NF-E2-Related Factor 2, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review